Routine executive hiring inducement with no immediate trading catalyst. Monitor for future pipeline updates or clinical data releases, which are the primary drivers for this pre-revenue biotech.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 11 $38.51entry
- T+1 · 2mo ago +2.70%α +3.15% · $39.55
- T+5 · 2mo ago +0.47%α +0.69% · $38.69
- T+20 · 6w ago −0.36%α −2.23% · $38.37
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna granted a 275,000-share non-qualified stock option inducement award to newly appointed CMO Rajiv Patni under the 2026 Inducement Plan, effective September 8, 2026. This is a routine hiring inducement for a biotech executive, not a material financial event. The filing has no revenue, earnings, or guidance data, and the stock option is standard for a new officer hire.
Key Facts
- Septerna granted a non-qualified stock option to purchase 275,000 shares to new CMO Rajiv Patni
- Grant effective September 8, 2026, under the 2026 Inducement Plan
- Award is an inducement material to employment per Nasdaq Listing Rule 5635(c)(4)
- No financial results, guidance, or material business developments disclosed
Financial Impact
275,000-share option grant; no dollar value stated
Risk Factors
- Potential dilution from option exercise, though immaterial relative to outstanding shares
- No revenue or near-term catalysts disclosed in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359956 |
Track record
25 reports on SEPN
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +55.96% at T+60 after the Apr 13, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $42.60 −0.00% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $42.60 +1.77% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $42.60 +18.61% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $42.60 −11.03% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Viewing Entry $38.51 to $38.69 Now $42.60 +10.62% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $42.60 +15.92% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers